fda warning letter glp-1 october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA issued 30 warning letters

Hair loss: the delayed side effect Hair loss related to GLP-1 therapy typically does not appear until months three to six, making it a delayed side effect that catches many users off guard

Zhang J, You L, Wu W, Wang X, Chrienova Z, Nepovimova E, et al

Estrogen promotes cutaneous wound healing via estrogen receptor independent of its antiinflammatory activities

Bn c th mang n m bc s c k thuc A.T Glutathione 600mg mua thuc trc tip ti nh thuc Trung Tm Thuc Central Pharmacy ti a ch: 85 V Trng Phng, Thanh Xun, H Ni

Bartenschlager, R., Frese, M

Its important to remember differences in trial design, patient populations, and dosing make direct comparisons imperfect